Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ROCKET PHARMACEUTICALS, INC.

(RCKT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/10/2021 06/11/2021 06/14/2021 06/15/2021 06/16/2021 Date
46.19(c) 46.18(c) 47.25(c) 46.5(c) 46.74(c) Last
213 290 195 741 309 381 177 463 335 613 Volume
+1.83% -0.02% +2.32% -1.59% +0.52% Change
More quotes
Financials (USD)
Sales 2021 10,0 M - -
Net income 2021 -162 M - -
Net cash position 2021 282 M - -
P/E ratio 2021 -18,0x
Yield 2021 -
Sales 2022 32,5 M - -
Net income 2022 -163 M - -
Net cash position 2022 144 M - -
P/E ratio 2022 -19,0x
Yield 2022 -
Capitalization 2 963 M 2 963 M -
EV / Sales 2021 267x
EV / Sales 2022 86,9x
Nbr of Employees 91
Free-Float 90,9%
More Financials
Company
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapy treatment options for rare, devastating diseases. The Company’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The Company’s lead clinical program is a LVV-based gene therapy for the... 
More about the company
Ratings of Rocket Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about ROCKET PHARMACEUTICALS, INC.
05/14ROCKET PHARMACEUTICALS  : Significant Insider Selling Reported in Shares of Rock..
MT
05/13INSIDER TRENDS : Rocket Pharmaceuticals Insider Extends 90-Day Selling Trend
MT
05/13ROCKET PHARMACEUTICALS  : Presents Positive Clinical Data from Fanconi Anemia, L..
BU
05/12ROCKET PHARMACEUTICALS  : —Updated Low Dose Results in RP-A501 Treatment f..
PU
05/11SECTOR UPDATE : Health Care Stocks Ending Tuesday Session Lower, But Biotech Sha..
MT
05/11ROCKET PHARMACEUTICALS  : UBS Adjusts Price Target on Rocket Pharmaceuticals to ..
MT
05/10ROCKET PHARMACEUTICALS  : Management's Discussion and Analysis of Financial Cond..
AQ
05/10ROCKET PHARMACEUTICALS, INC.  : Results of Operations and Financial Condition, R..
AQ
05/10ROCKET PHARMACEUTICALS : Q1 Earnings Snapshot
AQ
05/10ROCKET PHARMACEUTICALS  : Reports First Quarter 2021 Financial Results and Highl..
BU
04/27ROCKET PHARMACEUTICALS  : Announces Upcoming Clinical Data Presentations at the ..
BU
04/27ROCKET PHARMACEUTICALS, INC.  : Other Events (form 8-K)
AQ
04/14ROCKET PHARMACEUTICALS  : Reports Positive Long-Term Clinical Data from RP-L201 ..
BU
04/01INSIDER TRENDS : Insider at Rocket Pharmaceuticals Sale for Taxes Adds to 90-Day..
MT
04/01INSIDER TRENDS : Insider Acquires Rocket Pharmaceuticals Stock Via Option/Deriva..
MT
More news
News in other languages on ROCKET PHARMACEUTICALS, INC.
05/07EQS-ADHOC : HBM Healthcare Investments erzielt im Geschäftsjahr 2020/2021 einen ..
04/14USA  : Casa Bianca amplia lista candidati a commissario Fda
More news
Analyst Recommendations on ROCKET PHARMACEUTICALS, INC.
More recommendations
Chart ROCKET PHARMACEUTICALS, INC.
Duration : Period :
Rocket Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCKET PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Average target price 70,70 $
Last Close Price 46,74 $
Spread / Highest target 114%
Spread / Average Target 51,3%
Spread / Lowest Target 19,8%
EPS Revisions
Managers and Directors
NameTitle
Gaurav Shah President, Chief Executive Officer & Director
Carlos Garcia-Parada Chief Financial Officer
Roderick T. Wong Chairman
Jonathan David Schwartz Chief Medical Officer & SVP-Clinical Development
Kinnari Patel Chief Operating Officer & EVP-Development
Sector and Competitors
1st jan.Capitalization (M$)
ROCKET PHARMACEUTICALS, INC.-14.77%2 963
GILEAD SCIENCES, INC.15.57%85 397
WUXI APPTEC CO., LTD.21.14%65 765
REGENERON PHARMACEUTICALS8.38%54 626
BIONTECH SE150.06%52 693
VERTEX PHARMACEUTICALS-20.67%48 918